Localized
Localized
Advertisement
Emily MenendezLocalized | May 10, 2024
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Read More
Katy MarshallLocalized | May 7, 2024
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Zachary BessetteLocalized | May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Katy MarshallLocalized | May 4, 2024
Investigators found that the NCHT cohort demonstrated increased 3-year bPFS benefits compared to the NHT cohort.
Daniel Spratt, MDLocalized | April 17, 2024
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Emily MenendezProstate Cancer Diagnostics | April 10, 2024
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Steven Canfield, MDLocalized | April 9, 2024
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Zachary BessetteLocalized | April 9, 2024
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Emily MenendezLocalized | April 8, 2024
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
James Sylora, MDLocalized | April 3, 2024
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
Emily MenendezLocalized | March 21, 2024
Relugolix was approved in 2020 for the treatment of localized prostate cancer based on the efficacy seen in the HERO trial.
Katy MarshallLocalized | March 18, 2024
Part 1 of the new guidelines covered treatment decision-making during suspected BCR following radical prostatectomy.
Katy MarshallLocalized | March 18, 2024
Recommendations were included for patients with biochemical recurrence following radiation therapy.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Emily MenendezLocalized | February 15, 2024
Radical prostatectomy resulted in worse urinary incontinence for patients with localized prostate cancer.
Scott Eggener, MDASCO GU Symposium 2024 | January 30, 2024
Dr. Eggener describes the Stockholm3 test and reasons for validating it in an ethnically-diverse population.
Emily MenendezLocalized | January 8, 2024
No G3 or G4 GU or GI toxicities occurred in either treatment arm, and G2 toxicities were uncommon.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis continue their EMBARK discussions and recommendations for treating high-risk BCR prostate cancer.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis discuss the details of the NEJM phase 3 EMBARK study on enzalutamide in BCR prostate cancer.
Advertisement
Advertisement
Advertisement